Biomet's fourth-quarter results lack sparkle
This article was originally published in Clinica
Biomet's share price fell by more than 4% in after-hours trading on June 20 after the Warsaw, Indiana orthopaedics company released preliminary fourth-quarter sales figures at the low end of expectations. It also announced management changes in its EBI bone growth stimulation and external fixation business unit.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.